Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL199940 | 0.83 | ALDH1A1 (0.48) | PDCD1CD274CYP2A6ALDH1A1HPGD | |
| SCHEMBL3559815 | 0.81 | TSHR (0.43) | CYP2A6MYCALDH1A1NPC1RAB9A | |
| SCHEMBL616 | 0.78 | ESR2 (0.54) | KDM4EPDCD1CD274CYP2A6CYP2B6 | |
| SCHEMBL30612770 | 0.78 | CA12 (0.54) | KDM4EPDCD1CD274CYP2A6CYP2B6 | |
| SCHEMBL29706107 | 0.78 | ESR2 (0.54) | KDM4EPDCD1CD274CYP2A6CYP2B6 | |
| SCHEMBL29109491 | 0.76 | ESR2 (0.54) | KDM4ECYP2A6CYP2B6ADORA3ADORA2A | |
| Benzene SCHEMBL29008554 | 0.76 | PDCD1 (0.57) | KDM4EPDCD1CD274CYP2A6CYP2B6 | |
| Formaldehyde SCHEMBL29224547 | 0.76 | CA12 (0.53) | KDM4EPDCD1CD274CYP2A6CYP2B6 | |
| SCHEMBL192334 | 0.76 | PDCD1 (0.57) | KDM4EPDCD1CD274CYP2A6CYP2B6 | |
| SCHEMBL3559817 | 0.76 | ESR2 (0.44) | KDM4EPDCD1CD274CYP2A6CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653960-A4 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1653960-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC. (US) | 2006-05-10 | — | — | EP | claimed |
| US-20050215526-A1 | Melanin concentrating hormone receptor antagonist | AMGEN, INC. | 2005-09-29 | — | — | US | claimed |
| WO-2005019167-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN, INC. (US) | 2005-03-03 | — | — | WO | claimed |
| EP-2675800-A1 | FUNCTIONALIZED ANTHRACENE-CAPPED OLIGOTHIOPHENES AND ORGANIC SEMICONDUCTORS BASED ON THE SAME, USE THEREOF | Institute Of Chemistry, Chinese Academy Of Sciences (CN) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012079545-A1 | FUNCTIONALIZED ANTHRACENE-CAPPED OLIGOTHIOPHENES AND ORGANIC SEMICONDUCTORS BASED ON THE SAME, USE THEREOF | CHINESE ACADEMY OF SCIENCE INSTITUTE OF CHEMISTRY (CN) | 2012-06-21 | — | — | WO | disclosed |
| US-7659276-B2 | Melanin concentrating hormone receptor antagonist | AMGEN, INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090143405-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-7514438-B2 | Melanin concentrating hormone receptor antagonist | AMGEN, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1653960-A4 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN INC (US) | 2008-11-26 | — | — | EP | disclosed |
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| US-20050215526-A1 | Melanin concentrating hormone receptor antagonist | AMGEN, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005019167-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | AMGEN, INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | disclosed |
| EP-1354602-A1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | Sankyo Company, Limited (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | KDM4E 2238/4885PDCD1 4063/4885CD274 4551/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | KDM4E 2238/4885PDCD1 4063/4885CD274 4551/4885 |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | KDM4E 4720/4885PDCD1 4637/4885CD274 4743/4885 |
| US-20090143405-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONIST | MCHR1, MC1R, NPY1R | KDM4E 3530/4885PDCD1 4164/4885CD274 3620/4885 |
| US-20050215526-A1 | Melanin concentrating hormone receptor antagonist | MCHR1, MC1R, NPY1R | KDM4E 3530/4885PDCD1 4164/4885CD274 3620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.